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Abstract: Metabolic acidosis is a common complication in chronic kidney disease (CKD) patients, 
and is associated with an accelerated decline in renal function. Oral bicarbonate therapy has been 
used to counteract metabolic acidosis in CKD for decades. However, until recently, there have been 
very few intervention studies testing the effectiveness of bicarbonate therapy at improving 
metabolic acidosis or its consequences in patients with CKD. In this systematic review and meta-
analysis, we aimed to examine the outcomes of all published randomised controlled trials (RCTs) 
that investigated the effect of oral bicarbonate therapy in adults with CKD. Ovid MEDLINE®, 
EMBASE® and Cochrane Library were searched in mid-October 2018 for English literature, with no 
restrictions applied to the publication status or date. Seven RCTs that recruited 815 participants met 
our inclusion criteria after full text review. Oral bicarbonate supplementation resulted in a slightly 
higher estimated glomerular filtration rate (eGFR) (mean difference 3.1 mL/min per 1.73 m2; 95% CI 
1.3–4.9) and serum bicarbonate levels (mean difference 3.4 mmol/L; 95% CI 1.9–4.9) at the end of 
follow-up (three months to five years) compared to those given placebo or conventional CKD 
treatment. When limited to studies reporting outcomes at one year, the positive effect of oral 
bicarbonate therapy on eGFR was attenuated. There were no significant treatment effects in other 
parameters such as systolic blood pressure (BP) and weight. These findings should be interpreted 
with caution and further trial evidence is needed to establish the net overall benefit or harm of oral 
bicarbonate therapy in CKD. 
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1. Introduction 
More than 1.8 million people in England are known to have chronic kidney disease (CKD), while 
another million of the population are thought to have the condition but are yet to be diagnosed [1,2]. 
CKD can significantly reduce quality and quantity of life and may lead to the need for renal 
replacement therapy. Around 45,000 premature deaths are attributed to CKD annually in the United 
Kingdom [3]. Furthermore, the management of CKD places a substantial economic burden on 
healthcare systems across the globe, and healthcare expenditure has been noted to be inversely 
proportional to renal function [4]. The National Health Service (NHS) in England spent 
approximately £1.45 billion on CKD in 2009–2010 [1]. Given the impact of CKD on quality of life and 
healthcare expenditure, interventions that may slow the progression of CKD are of great importance. 
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Metabolic acidosis is frequently found in CKD patients, and becomes more common with 
worsening renal function [4]. Metabolic acidosis has been operationalised as serum bicarbonate levels 
that are consistently below 22 mmol/L [4–6]. It is associated with other pathophysiological changes 
including systemic inflammation, upregulation of parathyroid hormone receptors in osteoblasts and 
increased activity of osteoclasts; which leads to accelerated bone resorption and osteopenia, reduction 
of Na+-K+-ATPase activity in erythrocytes—resulting in impairment of myocardial contractility and 
heart failure, and reduced respiratory reserve and exhaustion of body buffer systems, which increases 
severity of acute intercurrent illnesses [4–10]. The degree of metabolic acidosis is directly associated 
with glomerular filtration rate GFR, and is due to the failure of the kidneys to produce ammonia, 
regenerate bicarbonate and excrete hydrogen ions [11]. Importantly, metabolic acidosis is associated 
with an accelerated decline in renal function, an association that may be causal in nature [12]. 
As part of CKD patients’ care, oral alkali such as bicarbonates and citrates, base-producing fruits 
and vegetables or low protein diets are commonly prescribed to avoid or correct metabolic acidosis. 
Oral bicarbonate therapy has been used to counteract metabolic acidosis in CKD for decades. 
However, until recently, there have been very few intervention studies testing the effectiveness of 
bicarbonate therapy at improving metabolic acidosis, or its consequences in patients with CKD, and 
there are no systematic reviews evaluating the effectiveness and safety of this approach. This is 
reflected by the current guidelines, which are still unable to make an evidence-based 
recommendation regarding the correction of mild-to-moderate acidosis in CKD [13]. To date, there is 
also no consensus on the optimal range for serum bicarbonate in CKD patients. The paucity of clear 
guidelines results in variability in clinical practice when prescribing oral bicarbonate therapy for 
patients with CKD and metabolic acidosis [13]. 
In this systematic review and meta-analysis, we aimed to examine the outcomes of all published 
randomised controlled trials (RCTs) that investigated the effect of oral bicarbonate therapy in non-
haemodialysis dependent adults with CKD. 
2. Methods 
2.1. Literature Search Strategy 
The review protocol was registered in the PROSPERO database (Ref: CRD42018112908) [14]. 
Three databases (Ovid MEDLINE®, EMBASE® and Cochrane Library) were searched in mid-October 
2018 for English literature, with no restrictions applied to the publication status or date. Grey 
literature was not searched. The full search strategy is presented in Appendix 1. 
2.2. Inclusion and Exclusion Criteria 
Our inclusion criteria were randomised controlled trials, availability of full text in English 
language, all aetiologies and severities of CKD, comparison of bicarbonate therapy with placebo or 
standard care, and any health-related outcome measures. Our exclusion criteria were children under 
the age of 18, people receiving haemodialysis and the comparison of bicarbonate therapy with active 
treatment. 
2.3. Study Selection 
Two reviewers independently screened all titles and abstracts. The bibliographies of selected 
articles were hand-searched for any other potentially relevant studies. Any uncertainties about study 
eligibility were discussed between reviewers, and if necessary, with a third reviewer. 
2.4. Data Extraction 
A data extraction form was designed by adapting and customising the Cochrane collaboration’s 
data collection form for intervention review—RCTs and non-RCTs [15]. Two independent assessors 
performed the data extraction. Data discrepancies were resolved by discussion and consensus 
between the two assessors. 
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2.5. Risk of Bias 
Risk of bias was evaluated using the Cochrane collaboration’s risk of bias tool [15]. Criteria 
assessed included random sequence generation, allocation concealment, blinding of participants and 
personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other 
biases. Risk was reported as low, high or unclear. Results from the assessment were subsequently 
tabulated using RevMan 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) to generate a risk 
of bias graphic and summary table [16]. 
2.6. Outcome Measures and Data Synthesis 
The primary outcome measure of interest was the rate of change in estimated glomerular 
filtration rate (eGFR). Secondary outcome measures were eGFR at the end of follow-up, mortality, 
blood pressure, number of patients proceeding to renal replacement therapy and quality of life. Meta-
analyses of these and any other health-related outcome measures were performed when there were 
at least three trials reporting the same outcome measure. The random effects model was used for 
continuous data and forest plots generated using RevMan 5.3. Statistical heterogeneity in treatment 
effects was determined using the I2 test. 
2.7. Subgroup Analysis 
Subgroup analyses were planned by mean study age, mean proportion of men and the duration 
of the study. 
3. Results 
3.1. Study Selection 
After deduplication, the search identified 307 potentially relevant articles, and 32 trials were 
shortlisted after reading titles and abstracts (see Figure 1). Seven trials that recruited 815 participants 
met the inclusion criteria after a full text review (see Table 1). Two trials were set in the USA and 
India, respectively, with one trial each from Italy, South Korea and the UK. 
 
Figure 1. Study flow diagram. 
J. Clin. Med. 2019, 8, 208 1 of 13 
 
Table 1. Characteristics of included randomised controlled trial. 
Study Location n 
Mean Age 
(Years) 
CKD Stage 
Bicarbonate Level Entry 
Criterion 
Intervention Comparator Duration 
Primary 
Outcome 
Mathur et al. 
2006 [17] 
India 40 41 
“Mild to moderate” CKD 
(creatinine <442 μmol/L). 
CKD stage not specified 
Not specified 
Oral bicarbonate 1.2 mEq/kg in 3 divided 
doses, titrated to maintain serum 
bicarbonate in range 22–26 mmol/L 
Placebo 3 months Not specified 
De Brito-
Ashurt et al. 
2009 [18] 
UK 134 55 4 or 5 
16 mmol/L < Bicarbonate 
< 19 mmol/L 
Oral bicarbonate 600 mg 3×/day, increased 
as needed to maintain serum bicarbonate > 
23 mmol/L 
Usual care 2 years 
Decline in 
creatinine 
clearance of >3 
mL/min/year 
Mahajan et 
al. 2010 [19] 
USA 120 51 
2 with hypertension and 
microalbuminuria 
Total CO2 > 24.5 mmol/L 
Oral bicarbonate 0.5 mEq/kg lean body 
weight 
Placebo 5 years 
eGFR decline 
rate 
Jeong et al.  
2014 [20] 
South 
Korea 
80 55 4 or 5 Total CO2 < 22 mmol/L 
Oral bicarbonate 1 g 3×/day, titrated to 
maintain serum bicarbonate > 22 mmol/L 
Usual care 12 months eGFR 
Goraya et al. 
2014 [21] 
USA 108 54 3 
22 mmol/L < Total CO2 < 
24 mmol/L 
Oral bicarbonate 0.3 mEq/Kg lean body 
weight in three divided doses 
Usual care 3 years eGFR 
Bellasi et al. 
2016 [22] 
Italy 145 65 
3b or 4; in patients with 
T2DM 
Bicarbonate < 24mmol/L 
Oral bicarbonate 0.5 mEq/kg twice daily, 
until serum bicarbonate 24–28 mmol/L 
Usual care 12 months 
Insulin 
resistance 
Dubey et al. 
2018 [23] 
India 188 50 3 and 4 Bicarbonate < 22mmol/L 
Oral bicarbonate titrated with weekly 
monitoring 
Usual care 6 months 
Mid-arm muscle 
circumference 
CKD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate; CO2: Carbon dioxide; T2DM: Type 2 diabetes mellitus. 
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3.2. Risk of Bias Analysis 
Three RCTs described utilisation of adequate randomisation processes [18,21,22] to minimise 
selection bias, while one study used patient’s identifying number [19], which was likely to have 
increased the risk of bias (see Figures 2 and 3). Two RCTs applied allocation concealment by 
employing a central randomisation process [22] or using opaque sequenced envelopes [23], but there 
was no mention of allocation concealment in the other studies. All studies had a high risk of 
performance bias due to the nature of the intervention, in which oral bicarbonate therapy was titrated 
and monitored to achieve desired serum bicarbonate levels. Two studies used placebo as a 
comparator [17,19], which might potentially reduce the risk of performance bias, but did not 
completely abolish it. 
 
Figure 2. Risk of bias graph (presented as percentages across all included studies) illustrating the 
review authors’ judgements about each risk of bias criterion. 
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Figure 3. Risk of bias table illustrating the review authors’ judgements about each risk of bias 
criterion. Green: Low risk of bias; Yellow: Unclear risk of bias; Red: High risk of bias. 
Two RCTs reported blinding of their outcome assessors [18,23] while it was unclear in the rest if 
this risk of bias was minimised or eliminated. All studies were deemed to have low attrition bias as 
the dropout rate was less than 10% and accounted for in each study. The missing outcomes were also 
thought to be insufficient to have a clinically relevant impact on the observed effect size. Two studies 
recorded all expected outcomes using measurements and analysis methods that were pre-specified 
[19,21], and therefore had a low reporting bias. Two RCTs were judged to have a high risk of bias 
because outcome measures were detailed with an unconventional outcome measure (decline in 
creatinine clearance) [18], and measurements (mean and 95% confidence interval (CI)) [23]. The 
remaining studies did not offer sufficient information to permit judgement about this criterion. 
3.3. Outcomes 
3.3.1. Serum Bicarbonate 
All seven RCTs studied serum bicarbonate levels following the randomisation of study 
participants (see Figure 4) [17–23]. Data from 707 patients were analysed; 57.9% were males and their 
mean age ranged from 37.5 ± 17 years to 65.5 ± 11.4 years. Serum bicarbonate levels were higher after 
oral bicarbonate therapy (mean difference 3.4 mmol/L; 95% CI 1.9–4.9) but the results were highly 
heterogeneous (I2 = 97%). 
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Figure 4. Forest plot comparing the effects of oral bicarbonate therapy and control on serum 
bicarbonate levels. Note: Boxes represent the mean difference between bicarbonate and control in 
individual trials. The boxes are proportional to the weight of each study in the analysis and the lines 
represent their 95% confidence interval (CI). The diamond represents the pooled mean difference, and 
its width represents its 95% CI. SD: Standard deviation; CI: Confidence interval; Tau2: Variance of the 
effect size across studies; Chi2: Weighted sum of squared differences between individual studies and 
the pooled effect across studies; df: Degrees of freedom; I2: Percentage of variation across studies that 
is due to heterogeneity; Z: Test for overall effect across all studies. 
3.3.2. eGFR and Serum Creatinine 
Six RCTs [18–23] investigated eGFR after randomising patients to oral bicarbonate therapy or 
placebo (see Figure 5). Data were not presented in a format that allowed the rate of change of eGFR 
(the primary outcome measure) to be analysed, so eGFR at the end of follow-up was used. A total of 
667 patients were analysed; 57.7% were males and their mean age ranged from 50.1 ± 11.6 years to 
65.5 ± 11.4 years. eGFR favoured bicarbonate therapy (mean difference 3.1 mL/min per 1.73 m2; 95% 
CI 1.3–4.9) but the analysis revealed moderately high heterogeneity (I2 = 68%). 
 
Figure 5. Forest plots comparing the effects of oral bicarbonate therapy and control on eGFR and 
serum creatinine levels. Note: Boxes represent the mean difference between bicarbonate and control 
in individual trials. The boxes are proportional to the weight of each study in the analysis and the 
lines represent their 95% confidence interval (CI). The diamond represents the pooled mean 
difference, and its width represents its 95% CI. SD: Standard deviation; CI: Confidence interval; Tau2: 
Variance of the effect size across studies; Chi2: Weighted sum of squared differences between 
individual studies and the pooled effect across studies; df: Degrees of freedom; I2: Percentage of 
variation across studies that is due to heterogeneity; Z: Test for overall effect across all studies. 
Four studies measured serum creatinine at the end of their follow-up period (see Supplementary 
Figure S1) [17,19,20,23]. Data from 361 patients were included; 61% were males and their mean age 
ranged from 37.5 ± 17 years to 55.8 ± 12.7 years. Compared with placebo and standard care for CKD, 
oral bicarbonate supplementation had non-significant effects on serum creatinine (p = 0.09). 
3.3.3. Systolic Blood Pressure 
Six studies recorded systolic blood pressure (BP) as an outcome measure (see Figure 6) [17–
19,21–23]. A total of 635 patients were included; 57.3% were males and their mean age ranged from 
37.5 ± 17 years to 65.5 ± 11.4 years. Oral bicarbonate therapy had uncertain effects on systolic BP when 
compared to placebo or conventional treatment for CKD (p = 0.19). 
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Figure 6. Forest plot comparing the effects of oral bicarbonate therapy and control on systolic blood 
pressure. Note: Boxes represent the mean difference between bicarbonate and control in individual 
trials. The boxes are proportional to the weight of each study in the analysis and the lines represent 
their 95% confidence interval (CI). The diamond represents the pooled mean difference, and its width 
represents its 95% CI. SD: Standard deviation; CI: Confidence interval; Tau2: Variance of the effect 
size across studies; Chi2: Weighted sum of squared differences between individual studies and the 
pooled effect across studies; df: Degrees of freedom; I2: Percentage of variation across studies that is 
due to heterogeneity; Z: Test for overall effect across all studies. 
3.3.4. Weight 
Five RCTs reported the weight of their patients at the conclusion of their studies (see Figure 7) 
[17,20–23]. 507 patients were analysed; 69.3% were males and their mean age ranged from 37.5 ± 17 
years to 65.5 ± 11.4 years. The effects of oral bicarbonate therapy on weight of CKD patients are 
uncertain (p = 0.3) and the results are highly heterogeneous (I2 = 87%). 
 
Figure 7. Forest plot comparing the effects of oral bicarbonate therapy and control on weight. Note: 
Boxes represent the mean difference between bicarbonate and control in individual trials. The boxes 
are proportional to the weight of each study in the analysis and the lines represent their 95% 
confidence interval (CI). The diamond represents the pooled mean difference, and its width 
represents its 95% CI. SD: Standard deviation; CI: Confidence interval; Tau2: Variance of the effect 
size across studies; Chi2: Weighted sum of squared differences between individual studies and the 
pooled effect across studies; df: Degrees of freedom; I2: Percentage of variation across studies that is 
due to heterogeneity; Z: Test for overall effect across all studies. 
3.3.5. Other Outcomes 
The rate of change of eGFR was intended as a primary outcome, but data from multiple trials 
were not presented in a format that enabled this parameter to be analysed, so eGFR at the end of 
follow-up was used. Other listed outcomes that were not available included mortality rate, number 
of patients proceeding to renal replacement therapy and quality of life. 
3.4. Subgroup Analyses 
Subgroup analyses were performed by the duration of the study, thereby eliminating one source 
of heterogeneity. These analyses were only possible for eGFR and serum bicarbonate at one year 
follow-up (see Supplementary Figures S2 and S3), as there were too few studies or insufficient data 
in other outcome measures to allow for meaningful analysis. 
Three studies investigated eGFR and serum bicarbonate levels at one year after the 
randomisation of patients to oral bicarbonate therapy or placebo treatment [18,20,22]. Of the 347 
patients that were analysed; 55.4% were males and their mean age ranged from 53.3 ± 13.5 years to 
65.5 ± 11.4 years. The effects of bicarbonate therapy on eGFR were non-significant when the duration 
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of the study was standardised at one year (p = 0.19). The heterogeneity of treatment results was lower 
than other analyses (I2 = 46%). Serum bicarbonate at one year was higher after oral bicarbonate 
therapy (mean difference 3.2 mmol/L, 95% CI 2.0–4.3), but there was still significant heterogeneity (I2 
= 66%). 
4. Discussion 
4.1. Outcomes 
Oral bicarbonate supplementation resulted in a slightly higher eGFR at the end of follow up 
(three months to five years) compared to those given placebo or conventional CKD treatment. 
Bicarbonate therapy also improved serum bicarbonate levels by an average of 3.2 mmol/L compared 
to the control arm, but we did not find any significant treatment effects in other parameters such as 
systolic BP and weight. 
These findings should be interpreted with caution due to a high level of heterogeneity between 
studies. The heterogeneity probably reflects the marked differences across trials, ranging from 
population demographics to dosing regimen and length of follow-up. Furthermore, the mean age of 
trial participants was remarkably low despite the increased prevalence of CKD in older people [1,2]. 
All but one trial recruited patients with a mean age below 56 years. Although most epidemiological 
studies observed that CKD was more common in women, all seven RCTs in this review enrolled more 
men than women [24]. This suggests that there may be a degree of selection bias in trial recruitment 
that may limit the generalisation of results in clinical practice. Some trials recruited atypical 
populations, e.g., those with stage 2 CKD with albuminuria due to hypertension [19] or those with 
CKD of unknown aetiology in India [17]. It is not clear that the observed treatment effects would be 
seen in more typical patients with CKD. Patients’ dietary intakes were not clearly accounted for, and 
this might have influenced the serum bicarbonate levels, as acid- and base-producing diets are known 
to skew bicarbonate levels. Patients also had various co-morbidities such as cardiovascular diseases 
and type 2 diabetes mellitus, but this confounding factor might be difficult to avoid when recruiting 
CKD patients, as most patients have at least one, if not more, co-morbidities. 
Almost all trials included in this analysis were open-label, and it is known that unmasked trial 
designs tend to overestimate the treatment effect size compared to placebo. Several trials adopted a 
‘treat to target’ approach for bicarbonate, in which doses were escalated in the intervention arm to 
try and reach a pre-defined bicarbonate level. Such approaches again tend to magnify treatment 
effects compared to the comparison of bicarbonate at a fixed dose with controls, although it can be 
argued that such an approach better approximates clinical practice. 
Another likely confounding factor is the duration of study. When limited to studies reporting 
outcomes at one year of follow-up, the positive effect of oral bicarbonate therapy on eGFR was 
attenuated and eGFR did not differ significantly between those on bicarbonate supplementation and 
placebo. All trials also recruited patients with a wide range of baseline bicarbonate levels (16 to 24 
mmol/L), and this may have had an influence on the observed response to treatment, such that studies 
that began with lower baseline bicarbonate levels might have witnessed a larger treatment effect size. 
Our results revealed that a modest total of 815 participants worldwide had been recruited into 
seven RCTs of bicarbonate therapy. It is highly likely that future studies will influence the results of 
the meta-analysis. The authors are aware of four further relevant RCTs that have published their 
protocols but are yet to report their results—BiCARB [13], UBI [25], SoBic [26] and BASE [27]. Their 
planned recruitment figures should more than double the number of participants in trials of 
bicarbonate treatment in CKD to date, as well as address current weaknesses in the evidence base, 
such as a lack of older people and data on physical function and quality of life. 
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4.2. Potential Adverse Effects of Bicarbonate Oral Therapy 
As with most medications, oral bicarbonate therapy comes with its own adverse effects and 
cautions. Sodium bicarbonate tablets are awkward to take, especially for older people with impaired 
swallowing and polypharmacy; the tablets are large and several tablets are usually required to be 
taken at one time or in a day [13]. The British National Formulary (BNF) listed abdominal discomfort 
and bloating as recognised side effects, which may lead to compliance issues in patients [13]. 600 mg 
sodium bicarbonate tablets taken three times daily cost the NHS £190 per patient per year, despite a 
lack of robust evidence supporting the efficacy of this treatment. 
Sodium bicarbonate tablets also contain 6 mmol of sodium in every 500 mg, which could 
contribute to hypertension and fluid overload if not monitored closely, especially in a population 
with impaired renal clearance [24]. This finding is corroborated by observational studies, which 
suggested that elevated serum bicarbonate levels were associated with an increased risk of heart 
failure in CKD patients [28]. It is therefore reassuring that this meta-analysis did not demonstrate any 
worsening of systolic blood pressure with bicarbonate therapy. 
The targeted serum bicarbonate level, dose and time of initiation are yet to be determined. 
Despite new evidence suggesting the range of potential benefits, overtreatment with oral alkali 
therapy may result in metabolic alkalosis, which is also associated with poor outcomes in patients 
with CKD [11]. An alkaline pH has also been shown to augment vascular calcification in animal 
models [11]. As arterial elasticity declines with age and older people are more likely to have CKD, 
caution has to be exercised when considering oral bicarbonate therapy. 
4.3. Strengths and Limitations 
To our knowledge, this is the first synthesis of trials investigating the effects of bicarbonate 
therapy. All fully published trials were included and we undertook meta-analysis where possible. 
However, there was substantial heterogeneity in all included studies. The seven RCTs had important 
differences in various parameters including population demographics, intervention regimes, 
outcome measures and duration of study. Additionally, studies were often at high risk of bias but 
poorer quality studies could not be excluded due to the limited number of published RCTs that suited 
our inclusion criteria. 
5. Conclusions 
Bicarbonate supplementation modestly improved eGFR and serum bicarbonate levels compared 
to placebo or conventional CKD management. Evidence of improvement in other health-related 
outcome measures was lacking. These findings should be interpreted with caution due to high 
heterogeneity and risk of bias in studies. Further trial evidence is needed to establish the net overall 
benefit or harm of oral bicarbonate therapy in CKD, and to define the target groups most likely to 
benefit from treatment. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Supplementary Figure 
S1. Forest plot comparing the effects of oral bicarbonate therapy and control on serum creatinine levels. 
Supplementary Figure S2. Forest plot comparing the effects of oral bicarbonate therapy and control on eGFR at 
one year. Supplementary Figure S3. Forest plot comparing the effects of oral bicarbonate therapy and control on 
serum bicarbonate levels at one year. 
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M.D.W. and R.L.S. drafted and revised the paper; all authors approved the final version of the manuscript. 
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Appendix 1: Search Strategy 
Table A1. Search strategy in MEDLINE. 
1 exp Bicarbonates [MeSH] or exp Sodium Bicarbonate [MeSH] or bicarbonates [tiab] 24,367 
2 
Chronic Kidney Disease or CKD [mp] or exp Renal Insufficiency, Chronic [MESH] or or 
Chronic Renal Insufficiency [tiab] 
127,737 
3 
(exp Bicarbonates [MeSH] or exp Sodium Bicarbonate [MESH] or bicarbonates [tiab]) and 
(Chronic Kidney Disease or CKD [mp] or exp Renal Insufficiency, Chronic [MESH] or or 
Chronic Renal Insufficiency [tiab]) 
812 
4 Limit 3 to RCT and English language 76 
exp: Explode; MeSH: Medical Subject Headings; tiab: Title or abstract; mp: Keyword; RCT: 
Randomised controlled trials. 
Table A2. Search strategy in EMBASE. 
1 exp Bicarbonate [MeSH] or Bicarbonate.mp 69,535 
2 
exp Chronic Kidney Failure [MeSH] or (chronic kidney disease or chronic kidney 
failure or chronic kidney insufficiency or chronic renal disease or chronic renal failure 
or chronic renal insufficiency).mp 
116,647 
3 
(exp Bicarbonate [MeSH] or Bicarbonate.mp) and (exp Chronic Kidney Failure 
[MeSH] or (chronic kidney disease or chronic kidney failure or chronic kidney 
insufficiency or chronic renal disease or chronic renal failure or chronic renal 
insufficiency).mp) 
2323 
4 Limit 3 to English language and exclude Medline journals and RCT 3 
exp: Explode; MeSH: Medical Subject Headings; mp: Keyword; RCT: Randomised controlled trials. 
Table A3. Search strategy in Cochrane. 
1 MeSH descriptor. [Bicarbonates] explode all trees 1201 
2 MeSH descriptor: [Sodium Bicarbonate] explode all trees 610 
3 #1 or #2 or (Bicarbonate *) 3123 
4 MeSH descriptor: [Renal Insufficiency, Chronic] explode all trees 5705 
5 
Chronic kidney disease or chronic kidney failure or chronic kidney insufficiency or 
chronic renal disease or chronic renal failure or chronic renal insufficiency 
13,858 
6 #4 or #5 13,524 
7 #3 and #6 in Trials 304 
MeSH: Medical Subject Headings; * (truncation symbol) is used to search for multiple variants of a 
word all at once. 
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